Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
Heidelberg
69120
Germany
Tel: 49-6221-65307-0
Fax: 49-6221-65307-77
Website: http://www.affimed.com/
Email: info@affimed.com
169 articles about Affimed GmbH
-
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
12/10/2022
Affimed N.V. provided a data update from the ongoing phase 1/2 study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas.
-
Setting the Stage for ASH 2022
12/9/2022
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs. -
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
11/7/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced data updates from two phase 1/2a trials with AFM24, the company’s tetravalent, bispecific innate cell engager, in patients with solid tumors.
-
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
11/4/2022
Affimed N.V. announced that it will release third quarter 2022 results and corporate update on Tuesday, November 15, 2022.
-
Affimed to Present at the 2022 Jefferies London Healthcare Conference
11/1/2022
Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.
-
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10/5/2022
Affimed N.V. announced that two abstracts with new data on the company’s novel innate cell engager AFM24 have been accepted for poster presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.
-
Zealand Pharma and Novo Nordisk linked resources to commercialize Zegalogue for severe hypoglycemia. For that and more from a busy week across the globe, see inside.
-
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
9/4/2022
Affimed N.V. announced that an abstract with clinical trial results of its innate cell engager AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology from 9-13 September 2022 in Paris.
-
Affimed to Present at Upcoming Investor Conferences in September 2022
9/1/2022
Affimed N.V. announced that the Company’s management will participate in the following investor conferences during the month of September 2022.
-
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
8/11/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the second quarter ended June 30, 2022 and provided updates on preclinical, clinical and corporate progress.
-
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
8/4/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022.
-
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
6/10/2022
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria.
-
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
6/1/2022
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.
-
Affimed to Present at the 2022 Jefferies Healthcare Conference
5/26/2022
Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 1:00 p.m. Eastern Daylight Time / 19:00 Central European Time.
-
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
5/26/2022
Affimed N.V. announced that three abstracts of clinical trial designs of its AFM24 innate cell engager have been published and will be presented at the American Society of Clinical Oncology Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.
-
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
5/24/2022
Affimed N.V. announced that it will release first quarter 2022 results and corporate update on Wednesday, June 1, 2022.
-
Affimed Announces Annual General Meeting of Shareholders - May 24, 2022
5/24/2022
Affimed N.V. announced that its 2022 Annual General Meeting of Shareholders will be held on June 22, 2022 at 09:00 a.m. CET at the Radisson Blu Hotel, Amsterdam City Center, Rusland 17, 1012 CK Amsterdam, the Netherlands.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
-
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)
5/12/2022
Affimed N.V. announced an upcoming poster presentation demonstrating the cytotoxic potential of its CD123/CD16A-targeting innate cell engager AFM28 at the Annual Meeting of the European Hematology Association to be held in Vienna, Austria on June 9 - 12, 2022.